Federated Hermes
NRIX icon

Federated Hermes’s Nurix Therapeutics NRIX Stock Holding History

Federated Hermes’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$178 – 2150
2025
Q1 		$178 Sell
15
-22,625
-100% -$378K ﹤0.01% 2041
2024
Q4 		$427K Sell
22,640
-19,564
-46% -$448K ﹤0.01% 1353
2024
Q3 		$948K Buy
+42,204
New +$956K ﹤0.01% 1135

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes's NRIX Position: Q2 2025 in Review

Federated Hermes sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 15 shares — an estimated $178 sold.

Federated Hermes first reported a position in NRIX in Q3 2024 and held it in 3 quarters. The position peaked at $948K in Q3 2024. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Federated Hermes reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Federated Hermes sold 15 Nurix Therapeutics shares in Q2 2025, an estimated $178.
  • Federated Hermes first reported a position in Nurix Therapeutics in Q3 2024 and held it in 3 quarters.
  • Federated Hermes's Nurix Therapeutics position peaked at $948K in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.